{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    6,
    7,
    9,
    11,
    13,
    19,
    23,
    39,
    41,
    46,
    48,
    51,
    59
  ],
  "modelUsed": "gemini-3-flash-preview",
  "confidence": 1.0,
  "documentStructure": {
    "documentContentReferences": [
      {
        "id": "ref_1",
        "name": "Investigator's Brochure Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "1",
        "sectionTitle": "INTRODUCTION",
        "description": "Reference to the Investigator's Brochure for nonclinical and clinical information."
      },
      {
        "id": "ref_2",
        "name": "Endpoint Definitions",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1",
        "sectionTitle": "Overview of Study Design",
        "description": "Reference to Section 9.2.2.4 for endpoint definitions."
      },
      {
        "id": "ref_3",
        "name": "Futility Analysis Reference",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1",
        "sectionTitle": "Overview of Study Design",
        "description": "Reference to Section 11.11.1 regarding the futility interim analysis."
      },
      {
        "id": "ref_4",
        "name": "DMC Details",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1",
        "sectionTitle": "Overview of Study Design",
        "description": "Reference to Section 11.12 for Data Monitoring Committee details."
      },
      {
        "id": "ref_5",
        "name": "Maintenance Study Eligibility",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.1",
        "sectionTitle": "Induction Study",
        "description": "Reference to Section 3.1.2 for maintenance study eligibility criteria."
      },
      {
        "id": "ref_6",
        "name": "Induction Therapy Stability",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.1",
        "sectionTitle": "Induction Study",
        "description": "Reference to Section 8.1.1 regarding maintenance of stable doses of UC-specific medical therapies."
      },
      {
        "id": "ref_7",
        "name": "Prohibited Medications",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.1",
        "sectionTitle": "Induction Study",
        "description": "Reference to Section 8.1.1.1 regarding restricted or prohibited medications."
      },
      {
        "id": "ref_8",
        "name": "Corticosteroid Tapering",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.2",
        "sectionTitle": "Maintenance Study",
        "description": "Reference to Section 8.1.2 for details on corticosteroid tapering."
      },
      {
        "id": "ref_9",
        "name": "Clinical Flare Criteria",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.2.1",
        "sectionTitle": "Management of Clinical Flare and Loss of Response",
        "description": "Reference to Section 9.1.4.1 for clinical flare criteria definitions."
      },
      {
        "id": "ref_10",
        "name": "Rescue Medication",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "3.1.2.1",
        "sectionTitle": "Management of Clinical Flare and Loss of Response",
        "description": "Reference to Section 8.1.2.1 for rescue medication eligibility."
      },
      {
        "id": "ref_11",
        "name": "Biologic Failure History",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference to Attachment 1 for history of failure to respond to biologic therapy."
      },
      {
        "id": "ref_12",
        "name": "Corticosteroid Failure Definition",
        "instanceType": "DocumentContentReference",
        "sectionNumber": "4.1",
        "sectionTitle": "Inclusion Criteria",
        "description": "Reference to Attachment 2 for definitions of inadequate response to corticosteroids."
      }
    ],
    "commentAnnotations": [
      {
        "id": "annot_1",
        "text": "Janssen Research & Development is a global organization that operates through different legal entities in various countries. The term 'sponsor' is used throughout the protocol to represent these various legal entities.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Title Page",
        "pageNumber": 1
      },
      {
        "id": "annot_2",
        "text": "All subjects will undergo QuantiFERON-TB Gold testing. In countries where the QuantiFERON-TB Gold test is not registered/approved, TB skin testing will also be required (recommended but not required for study centers in Ukraine if tuberculin is not available).",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Time and Events Schedule: Induction Study",
        "pageNumber": 8
      },
      {
        "id": "annot_3",
        "text": "The screening endoscopy must be performed within 2 weeks before the I-0 visit. The Mayo endoscopy subscore assessed by the central reader will be used to determine eligibility.",
        "annotationType": "Footnote",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Time and Events Schedule: Induction Study",
        "pageNumber": 14
      },
      {
        "id": "annot_4",
        "text": "Vital signs include temperature, pulse/heart rate, respiratory rate, and blood pressure.",
        "annotationType": "Clarification",
        "instanceType": "CommentAnnotation",
        "sourceSection": "Safety Evaluations",
        "pageNumber": 10
      }
    ],
    "studyDefinitionDocumentVersions": [
      {
        "id": "ver_1",
        "versionNumber": "Original Protocol",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-03-17",
        "description": "Initial release of the protocol.",
        "amendmentNumber": "N/A"
      },
      {
        "id": "ver_2",
        "versionNumber": "Amendment 1",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2015-07-14",
        "description": "Substantial amendment to address health authority feedback and clarify LTE dosing.",
        "amendmentNumber": "1"
      },
      {
        "id": "ver_3",
        "versionNumber": "Amendment 2",
        "status": "Approved",
        "instanceType": "StudyDefinitionDocumentVersion",
        "versionDate": "2016-04-20",
        "description": "Substantial amendment to address health authority requests for additional data collection (Bristol Stool Form Scale) and US-specific definitions.",
        "amendmentNumber": "2"
      }
    ],
    "summary": {
      "referenceCount": 12,
      "annotationCount": 4,
      "versionCount": 3
    }
  }
}